GlassScriptPhysician profile
Rizwan A Karatela
NPI 1407830904
$5,168.55
in general payments reported to CMS, 2019-2025
22 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $846 · 2021: $810 · 2022: $832 · 2023: $1,226 · 2024: $428 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $707.36 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $687.81 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $572.40 | 2019-2023 | Jardiance |
| Medtronic, INC. | $456.29 | 2024-2025 | Azure Xt Dr Mri Surescan, Linq II, Cobalt Dr Mri Surescan |
| Astrazeneca Pharmaceuticals LP | $414.54 | 2019-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $388.10 | 2019-2023 | Camzyos |
| Abbott Laboratories | $309.04 | 2019-2023 | Aveir |
| Janssen Pharmaceuticals, INC | $301.12 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $256.10 | 2021-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $241.88 | 2019-2023 | |
| Esperion Therapeutics, INC. | $176.09 | 2020-2023 | Nexletol |
| Biosense Webster, INC. | $142.03 | 2024 | Qdot Micro Catheter |
| Boston Scientific Corporation | $110.13 | 2022-2023 | Watchman Access System, Watchman Flx, Bodyguardian |
| Amarin Pharma, INC. | $101.72 | 2020-2021 | |
| Pfizer INC. | $98.79 | 2019-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $64.07 | 2023 | Ozempic |
| Regeneron Healthcare Solutions, INC. | $37.37 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $31.75 | 2023 | Opsumit, Uptravi |
| Akcea Therapeutics, INC. | $21.10 | 2020 | |
| Medtronic Vascular, INC. | $17.76 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.27 | 2021 | |
| Impulse Dynamics (USA) INC. | $15.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwan Karatela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.